ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...

The dream of a completely closed-loop system for diabetes management is now closer than ever for many Type 1 diabetes patients, thanks to the widespread U.S. launch of a completely automated, ...

Insulet Corporation PODD recently announced the commercial introduction of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for people with type 1 diabetes (T1D) who are two years of age ...

Insulet PODD delivered outstanding first-quarter performance, fueled by the rollout of the new Omnipod 5, which has been on fire since regulatory approval was received last fall. Though management ...

The Omnipod 5 will be immediately available for people ages 6 to 70. A new technology for people with Type 1 diabetes, one that has been nearly a decade in the making, has been approved by the U.S.

With little direct competition in patch pumps, Insulet PODD has been able to convert more users to its innovative, tubeless insulin pump. We expect meaningful profitability gains over the next five ...

Please provide your email address to receive an email when new articles are posted on . The FDA has cleared the first tubeless hybrid closed-loop insulin delivery system for use by children aged 2 to ...